#wegovy

#wegovy

The French state will soon partially reimburse the cost of weight-loss drugs Wegovy and Mounjaro for severely obese patients, expanding access to the expensive drugs, two informed sources told AFP on Wednesday. Wegovy, produced by Danish pharmaceutical company Novo Nordisk, and Eli Lilly's Mounjaro are among a new generation of weight-loss drugs that have proven remarkably effective, hugely popular and lucrative in the past few years, though they do have some drawbacks.

Lilly's fourth quarter revenue reached $19.29 billion, up 42.6% year-over-year, powered almost entirely by two products. Mounjaro generated $7.41 billion, up 110%, while Zepbound added $4.26 billion, up 123%.

After having "constructive conversations with stakeholders," Hims decided to stop offering the treatment, the company said in a post on X Saturday.

U.S. regulators on Monday gave the green light to a pill version of the blockbuster weight-loss drug Wegovy, the first daily oral medication to treat obesity. The U.S. Food and Drug Administration's approval handed drugmaker Novo Nordisk an edge over rival Eli Lilly in the race to market an obesity pill. Lilly's oral drug, orforglipron, is still under review. Both pills are GLP-1 drugs that work like widely used injectables to mimic a natural hormone that controls appetite and feelings of fullness.